한글목차

세계의 ARMET 유사 단백질 1 시장 전망은 대학 및 연구센터 시장에서의 기회에 유망시되고 있습니다. 세계의 ARMET 유사 단백질 1 시장은 2025-2031년 연평균 복합 성장률(CAGR) 8.0%로 성장할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 신경 보호 단백질에 대한 수요가 증가하고 단백질 연구에 대한 투자가 증가하며 신경 질환 연구가 증가하는 것입니다.

• Lucintel의 예측에서는 유형별로는 순도 95% 이상이 예측 기간 중에 높은 성장을 이룰 전망입니다.
• 용도별로는 연구센터가 보다 높은 성장이 예상됩니다.
• 지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장이 예상됩니다.

ARMET 유사 단백질 1 시장의 새로운 동향

ARMET 유사 단백질 1 시장은 그 광범위한 생물학적 기능에 대한 과학적 이해 증가와 함께 역동적인 변화를 이루고 있습니다. 개발 동향은 ARMET 유사 단백질 1의 치료 가능성 및 기초 연구, 신약 개발, 진단 기회에서 역할에 대한 인식이 높아지고 있음을 보여주고 있습니다.

• 신경 퇴행성 질환의 초점 : ARMET/ARP는 파킨슨 병과 같은 신경 퇴행성 질환의 치료 표적으로 점점 각광을 받고 있습니다. 도파민성 뉴런의 생존을 촉진하고 GABA 작용성 전달을 제어하는 확립된 기능은 신경 세포 손실에 대항하기 위한 약물 개발 및 유전자 치료 전략의 유망한 후보가 되고 있습니다.
• 소포체 스트레스 및 세포 생존 연구 : 소포체(ER) 스트레스 반응과 세포 생존에서 ARMET/ARP의 중요한 역할을 지적하는 목소리가 높아지고 있습니다. 이 동향은 다양한 세포환경에서 ARMET/ARP의 역할을 이해하기 위한 연구를 추진하고 단백질의 미스폴딩과 세포 스트레스를 특징으로 하는 조건에 대한 인사이트를 제공합니다.
• 유전자 치료법 : 치료 용도를 위해 ARMET/ARP를 투여하는 유전자 치료 연구는 흥미로운 새로운 동향입니다. ARMET/ARP 유전자를 표적 세포나 조직에 직접 투여함으로써 ARMET/ARP의 보호 작용을 강화하고 일정한 단백질 수준이 필수적인 지속성 신경퇴행성 질환에 대한 장기적인 치료 솔루션을 제공하려고 합니다.
• 재조합 단백질 생산 : 연구 및 전임상 시험을 위한 고순도 재조합 ARMET/ARP 단백질 수요가 증가하고 있습니다. 이는 기능 분석, 구조 분석 및 후보 약물의 스크리닝에 사용하기 위해 충분히 특성화된 단백질이 필요하기 때문에 단백질 발현 및 정제 기술의 개발을 지원합니다.
• 바이오 마커 발견 : ARMET/ARP를 질병의 바이오 마커로 연구하기 위한 노력이 진행 중입니다. 소포체 스트레스 및 저산소 상태에서의 ARMET/ARP의 유도와 분비는 세포장애나 질환 진행의 마커로서의 유용성을 나타내고 있으며, 신경질환이나 대사성질환에서 새로운 진단 검정에 문을 열고 있습니다.

이러한 새로운 동향은 목표를 겨냥한 치료법의 혁신을 촉진하고 진단 능력을 높이고 다양한 생물학적 기능에 대한 최첨단 연구를 지원함으로써 ARMET 유사 단백질 1 시장을 본질적으로 재정의하고 있습니다. 이 변화는 새로운 용도를 창출하고 암멧 클리니컬 요구를 충족시키는 시장 규모를 확대할 가능성을 가지고 있습니다.

ARMET 유사 단백질 1 시장의 최근 동향

ARMET 유사 단백질 1 시장은 주로 세포 스트레스, 신경 보호, 질병의 병리학적 기능에 관한 과학적 지식 증가에 힘입어 큰 진전을 이루고 있습니다. 이러한 개발은 치료에 대한 용도 가능성과 핵심 생물학적 과정의 깊은 이해에 대한 문을 열고 있습니다.

• 신경 퇴행의 치료 가능성 : 새로운 연구에서 ARMET/ARP는 도파민성 뉴런의 생존을 선택적으로 유도하는 것이 점점 강조되고 있습니다. 이러한 진보로 ARMET/ARP는 파킨슨병 및 기타 신경퇴행성 질환의 치료 표적이 될 수 있으며, 이러한 불편한 질환에 대한 약물 개발에 대한 연구 자금과 투자를 끌어들이고 있습니다.
• 소포체 스트레스에서의 역할 : ARMET/ARP는 소포체 스트레스를 완화하고 소포체 스트레스가 개재하는 세포사를 억제하는 중요한 역할을 담당하고 있다는 것이 실험에 의해 밝혀졌습니다. 이 정보는 다양한 스트레스 요인에 대한 세포 보호 전략의 개발에 필수적이며 당뇨병과 허혈과 같은 질병의 치료에 기대됩니다.
• 분비 인자로서의 동정 : ARMET/ARP가 스트레스나 저산소 조건하에서 ER/SR로부터 분비되어 상향조절된다는 동정은 중요한 개발입니다. 이 특징은 세포 외에서의 성질을 이용할 수 있기 때문에 진단용 바이오마커나 주사 가능한 치료제의 창조에 유력한 후보가 됩니다.
• GABA 작동성 전송 조정 : 최근에, ARMET/ARP가 도파민 작동성 뉴런에 GABA 작동성 전달을 조정하는 것으로 나타났습니다. 이것은 세포의 생존에 그치지 않고, 신경 회로의 미조정에 있어서의 기능을 시사하고, 치료 목적의 표적이 될 수 있는 신경 보호 메커니즘에 대한 인사이트를 제공합니다.
• 재조합 단백질의 가용성 및 조사 도구 : 고순도의 재조합 ARMET/ARP 단백질과 관련 연구 도구의 가용성이 높아짐에 따라 과학의 진보가 가속되었습니다. 이러한 도구는 상세한 기능 분석, 약물 스크리닝, 시험관내 및 생체내 모델의 구축 등을 가능하게 하여 생물학적 활성 및 치료 용도에 대한 추가 연구를 진행하고 있습니다.

이러한 진보는 특히 신경퇴행성 질환에서 ARMET-유사 단백질 1의 치료 용도에 대한 조사를 가속화하고 창약 표적 및 바이오마커 후보로서의 가능성을 높임으로써 ARMET-유사 단백질 1 시장에 깊은 영향을 미치고 있습니다. ARMET 유사 단백질 1 시장은 보다 적은 정보 제공형의 연구 지향이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경 및 분류
• 공급망

제3장 시장 동향 및 예측 분석

• 거시경제 동향 및 예측
• 업계의 촉진요인 및 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 ARMET 유사 단백질 1 시장 : 유형별

• 개요
• 유형별 매력 분석
• 순도 95% 미만 : 동향 및 예측(2019-2031년)
• 순도 95% 이상 : 동향 및 예측(2019-2031년)

제5장 세계의 ARMET 유사 단백질 1 시장 : 용도별

• 개요
• 용도별 매력 분석
• 대학 : 동향 및 예측(2019-2031년)
• 연구센터 : 동향 및 예측(2019-2031년)
• 기타 : 동향 및 예측(2019-2031년)

제6장 지역별 분석

• 개요
• 세계의 ARMET 유사 단백질 1 시장 : 지역별

제7장 북미의 ARMET 유사 단백질 1 시장

• 개요
• 북미의 ARMET 유사 단백질 1 시장 : 유형별
• 북미의 ARMET 유사 단백질 1 시장 : 용도별
• 미국의 ARMET 유사 단백질 1 시장
• 멕시코의 ARMET 유사 단백질 1 시장
• 캐나다의 ARMET 유사 단백질 1 시장

제8장 유럽의 ARMET 유사 단백질 1 시장

• 개요
• 유럽의 ARMET 유사 단백질 1 시장 : 유형별
• 유럽의 ARMET 유사 단백질 1 시장 : 용도별
• 독일의 ARMET 유사 단백질 1 시장
• 프랑스의 ARMET 유사 단백질 1 시장
• 스페인의 ARMET 유사 단백질 1 시장
• 이탈리아의 ARMET 유사 단백질 1 시장
• 영국의 ARMET 유사 단백질 1 시장

제9장 아시아태평양의 ARMET 유사 단백질 1 시장

• 개요
• 아시아태평양의 ARMET 유사 단백질 1 시장 : 유형별
• 아시아태평양의 ARMET 유사 단백질 1 시장 : 용도별
• 일본의 ARMET 유사 단백질 1 시장
• 인도의 ARMET 유사 단백질 1 시장
• 중국의 ARMET 유사 단백질 1 시장
• 한국의 ARMET 유사 단백질 1 시장
• 인도네시아의 ARMET 유사 단백질 1 시장

제10장 기타 지역의 ARMET 유사 단백질 1 시장

• 개요
• 기타 지역의 ARMET 유사 단백질 1 시장 : 유형별
• 기타 지역의 ARMET 유사 단백질 1 시장 : 용도별
• 중동의 ARMET 유사 단백질 1 시장
• 남미의 ARMET 유사 단백질 1 시장
• 아프리카의 ARMET 유사 단백질 1 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 구매자의 협상력
  • 공급기업의 협상력
  • 대체품의 위협
  • 신규 참가업체의 위협
• 시장 점유율 분석

제12장 기회 및 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 유형별 성장 기회
  • 용도별 성장 기회
• 세계 ARMET 유사 단백질 1 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증 및 라이선싱
  • 합병, 인수, 계약, 제휴 및 합작 사업

제13장 밸류체인 전체에 걸친 주요 기업의 기업 프로파일

• Competitive Analysis
• Thermo Fisher Scientific
• Bio-Techne
• Scientists Helping Scientists
• Abcam Limited
• FUJIFILM Irvine Scientific
• BD Biosciences
• Bio-Rad Laboratories
• BPS Bioscience
• Elabscience
• Yisheng Biotechnology

제14장 부록

• 도표 일람
• 표 목록
• 조사 방법
• 면책사항
• 저작권
• 약어 및 기술 단위
• 미국에 대해
• 미국 문의

영문목차

The future of the global ARMET-like protein 1 market looks promising with opportunities in the university and research center markets. The global ARMET-like protein 1 market is expected to grow with a CAGR of 8.0% from 2025 to 2031. The major drivers for this market are the rising demand for neuroprotective proteins, the growing investment in protein research, and the increase in neurological disease studies.

• Lucintel forecasts that, within the type category, purity >=95% is expected to witness higher growth over the forecast period.
• Within the application category, research center is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the ARMET-like Protein 1 Market

The ARMET-like protein 1 market is undergoing dynamic changes with increasing scientific understanding of its wide-ranging biological functions. The developing trends continue to demonstrate escalating awareness of its therapeutic potential and its role in basic research, developing new drug development and diagnostic opportunities.

• Neurodegenerative Disease Focus: ARMET/ARP is increasingly highlighted as a therapeutic target for neurodegenerative conditions such as Parkinson's disease. Its established function to enhance dopaminergic neuron survival and regulate GABAergic transmission makes it a promising candidate for drug development and gene therapy strategies to counteract neuronal loss.
• ER Stress and Cell Survival Studies: Measures are increasingly pointing to an essential role of ARMET/ARP in endoplasmic reticulum (ER) stress response and cell survival. The trend is propelling studies into an understanding of its role in diverse cellular milieus, providing insights into conditions featuring protein misfolding and cellular stress.
• Gene Therapy Methods: Investigation of gene therapy to administer ARMET/ARP for therapeutic applications is a fascinating emerging trend. Through direct administration of the ARMET/ARP gene into target cells or tissues, scientists seek to enhance its protective actions, providing a long-term therapeutic solution for persistent neurodegenerative disease in which constant protein levels are essential.
• Recombinant Protein Production: There is increasing demand for high-purity recombinant ARMET/ARP protein for research and pre-clinical investigations. This is necessitated by the requirement for well-characterized protein to be used for functional assays, structural analysis, and candidate drug screening, supporting development in protein expression and purification technologies.
• Biomarker Discovery: Efforts are underway to investigate ARMET/ARP as a potential biomarker for disease conditions. Its induction and secretion upon ER stress and hypoxia indicate its usefulness as a marker of cellular distress or disease progression, leaving the door open for new diagnostic assays in neurological and metabolic diseases.

These nascent trends are inherently redefining the ARMET-like protein 1 market by catalyzing targeted therapeutic innovation, increasing diagnostic capacity, and supporting cutting-edge research into its diverse biological functions. This change has the potential to release new applications and increase the size of the market in meeting unmet clinical needs.

Recent Developments in the ARMET-like Protein 1 Market

The ARMET-like protein 1 market is undergoing considerable advancements, mainly fueled by growing scientific knowledge on its functions in cellular stress, neuroprotection, and pathology of disease. These developments are opening doors for possible therapeutic applications and a better understanding of core biological processes.

• Therapeutic Potential in Neurodegeneration: Emerging research more and more emphasizes ARMET/ARP's selective induction of dopaminergic neuron survival. This advance makes it a potential therapeutic target for Parkinson's disease and other neurodegenerative disorders, drawing research funds and investment into drug development for these crippling conditions.
• Role in Endoplasmic Reticulum Stress: Experiments have also clarified ARMET/ARP's vital role in alleviating endoplasmic reticulum (ER) stress and suppressing ER stress-mediated cell death. This information is critical to the development of cell-protecting strategies against many different stressors and holds promise for treating diseases such as diabetes and ischemia.
• Identification as a Secreted Factor: Identification that ARMET/ARP is secreted and upregulated by the ER/SR under stress and hypoxia conditions is an important development. This feature makes it a strong candidate for creating diagnostic biomarkers or injectable therapeutic compounds because its extracellular nature can be exploited.
• Modulation of GABAergic Transmission: Recent evidence shows that ARMET/ARP modulates GABAergic transmission to dopaminergic neurons. This provides insight into its mechanisms of neuroprotection beyond cell survival to propose a function in the fine-tuning of neural circuits, potentially to be targeted for therapeutic purposes.
• Recombinant Protein Availability and Research Tools: The heightened availability of high-purity recombinant ARMET/ARP proteins and associated research tools has expedited scientific advancements. These tools enable detailed functional analyses, drug screening, and construction of in vitro and in vivo models to further investigate its biological activities and therapeutic uses.

These advancements are deeply affecting the ARMET-like protein 1 market by speeding up research into its therapeutic uses, specifically in neurodegenerative disorders, and increasing its potential as a drug discovery target and biomarker candidate. The market is becoming more targeted and informed research-oriented.

Strategic Growth Opportunities in the ARMET-like Protein 1 Market

The ARMET-like protein 1 market offers strong strategic growth opportunities through diversified applications stimulated by its newly uncovered roles in cell biology and disease pathology. Harnessing these applications can unlock tremendous market potential and promote advances in medical therapies and basic scientific knowledge.

• Neuroprotective Therapies Development: An important opportunity is the development of ARMET/ARP-based neuroprotective medicines for disorders such as Parkinson's disease. This encompasses gene therapies to increase its expression in the disease-affected neurons or small molecule medicines that mimic or enhance its neuroprotective effects, which address high unmet medical need.
• ER Stress-Associated Disorders: Another emerging area is the targeting of ER stress-associated disorders. By creating therapeutics that capitalize on ARMET/ARP's potential to block ER stress-mediated cell death, firms are able to treat a variety of conditions from diabetes (protection of pancreatic beta-cells) through ischemic damage, holding diverse therapeutic potential.
• Biomarker Diagnostics of Cellular Stress: There is potential to create diagnostic markers using ARMET/ARP as a biomarker of cellular stress or particular diseases. As ARMET/ARP is secreted during stress, its concentration in body fluids might be an indicator of disease severity or response to therapy, creating new diagnostic kits.
• Research Reagents and Tools: Ongoing market expansion for high-quality recombinant ARMET/ARP protein and associated antibodies and assays for fundamental research. With expanding knowledge of its role, demand for accurate research tools will grow, enabling drug discovery and functional studies in academic and industrial environments.
• Combination Therapies for Multifaceted Diseases: Combination therapy using ARMET/ARP together with other drugs for multifaceted diseases presents synergistic possibilities. For instance, the combination of ARMET/ARP with anti-inflammatory agents could provide more effective therapeutic outcomes in neuroinflammation-related diseases, making way for new, multi-modal therapies.

These strategic opportunities for growth are set to have a positive impact on the ARMET-like protein 1 market by propelling innovation in therapeutic discovery, increasing diagnostic sensitivity, and broadening its use in basic and translational research. Attention to these areas will result in market growth and better patient outcomes.

ARMET-like Protein 1 Market Driver and Challenges

The ARMET-like protein 1 market is heavily driven by a dynamic interplay of technological innovation, economic factors, and changing regulatory environments. While its multifaceted biological functions command substantial interest and investment, inherent complications associated with its complex mechanisms and therapeutic translation need to be addressed to unlock fully its market potential.

The factors responsible for driving the ARMET-like protein 1 market include:

1. Evolution of Knowledge on Disease Pathways: Greater scientific clarification of ARMET/ARP's functions in neuroprotection, ER stress response, and cell survival stimulates market interest. This greater comprehension stimulates research into its therapeutic applications in diseases such as Parkinson's and diabetes, with investment into drug discovery and development.

2. Increased Prevalence of Neurodegenerative Disorders: The increasing worldwide prevalence of neurodegenerative disorders, compounded by the aging population, presents a compelling demand for efficacious treatments. ARMET/ARP's neuroprotection on dopaminergic neurons makes it an attractive candidate, driving R&D in this high-requiring therapeutic region.

3. Advances in Protein Research Technologies: Advances in recombinant protein production, gene editing, and cell assay technologies enable more accurate exploration and manipulation of ARMET/ARP. These technology drivers lead to faster drug candidate identification and validation, driving market growth through improved research capabilities.

4. Increased R&D Funding in Biotechnology: Increased public and private sector investment in biotechnology and pharmaceutical R&D, including for new therapeutic targets, has a direct benefit to the ARMET/ARP market. Basic research and translational study funding enables the creation of new applications and products.

5. Potential for Multi-Disease Applications: ARMET/ARP participation in various cellular processes such as neuroprotection, stress response, and metabolic control indicates wide therapeutic scope. This broad applicability invites increased research interest and investment as it promises solutions to various unmet medical requirements.

Challenges in the ARMET-like protein 1 market are:

1. Protein Function and Delivery Complexity: The multimodal and context-sensitive functions of ARMET/ARP, together with difficulty in efficient delivery of proteins to target tissue such as the brain, represent a major challenge. Developing stable, safe, and efficient delivery mechanisms for therapeutic use is a primary technical challenge.

2. Prohibitively High Development Expense for Biopharmaceuticals: Formulating protein medicines or gene therapies with ARMET/ARP is by nature a high-capital affair, with heavy investment in research, trials, and production. The prohibitively high R&D and manufacturing expense may hinder market entry and decelerate commercialization.

3. Regulatory Pathways and Approval: Navigating intricate and dynamic regulatory pathways for new biological therapeutics such as ARMET/ARP is a key challenge. Proving safety, efficacy, and uniform quality to global regulatory agencies takes considerable data and time and influences market access and commercial feasibility.

The market of ARMET-like protein 1 is defined by tremendous scientific potential backed by its rich biological functions, most notably neuroprotection and cellular stress. But it will be vital to overcome the intrinsic challenges of protein delivery, the economic burden of biopharmaceutical development, and the strict regulatory standards for its broad clinical transition and market growth.

List of ARMET-like Protein 1 Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies ARMET-like protein 1 companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ARMET-like protein 1 companies profiled in this report include-

• Thermo Fisher Scientific
• Bio-Techne
• Scientists Helping Scientists
• Abcam Limited
• FUJIFILM Irvine Scientific
• BD Biosciences
• Bio-Rad Laboratories
• BPS Bioscience
• Elabscience
• Yisheng Biotechnology

ARMET-like Protein 1 Market by Segment

The study includes a forecast for the global ARMET-like protein 1 market by type, application, and region.

ARMET-like Protein 1 Market by Type [Value from 2019 to 2031]:

• Purity<95%
• Purity >=95%

ARMET-like Protein 1 Market by Application [Value from 2019 to 2031]:

• University
• Research Center
• Others

ARMET-like Protein 1 Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the ARMET-like Protein 1 Market

ARMET-like protein 1 market is gathering momentum in the biopharmaceutical and research industry with its multifunctional nature in cellular functions, especially neuroprotection and stress response. Emerging trends are inclined towards its therapeutic use in neurodegenerative conditions and its application in investigating fundamental biological processes, triggering more research and development activities in major global markets.

• United States: The US market is observing more research into ARMET-like protein 1, especially regarding its neuroprotective capabilities. Firms and universities are investigating its potential for the treatment of Parkinson's disease and other neurological disorders, which is fueling investment in recombinant protein manufacturing and drug discovery programs.
• China: China is increasingly interested in fundamental research and therapeutic prospects of ARMET-like proteins. Government support and biotechnology sectors that are expanding are funding research on its role in different diseases and how it could be a therapeutic target, leading to more science papers published on these topics.
• Germany: In Germany, research centers are aggressively studying the cellular pathways and mechanisms including ARMET-like protein 1, particularly endoplasmic reticulum stress and cell survival. Such emphasis on root biology helps to better understand it, which then helps inform future product development and therapeutic approaches.
• India: India's biotech industry is experiencing early but increasing interest in protein research, such as ARMET-like proteins. Although still largely in the realm of academic research, there is promise for collaborations and the development of low-cost production of recombinant proteins, considering India's robust pharmaceutical manufacturing sector.
• Japan: Japan is actively involved in cutting-edge molecular biology studies with an emphasis on protein functionality. Studies of ARMET-like protein 1 would presumably be concentrated on its involvement in neurological well-being and cellular homeostasis, which could result in new diagnostic reagents or therapeutic agents in the future.

Features of the Global ARMET-like Protein 1 Market

• Market Size Estimates: ARMET-like protein 1 market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: ARMET-like protein 1 market size by type, application, and region in terms of value ($B).
• Regional Analysis: ARMET-like protein 1 market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the ARMET-like protein 1 market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ARMET-like protein 1 market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the ARMET-like protein 1 market by type (purity<95% and purity >=95%), application (university, research center, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global ARMET-like Protein 1 Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Purity<95%: Trends and Forecast (2019-2031)
• 4.4 Purity >=95%: Trends and Forecast (2019-2031)

5. Global ARMET-like Protein 1 Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 University: Trends and Forecast (2019-2031)
• 5.4 Research Center: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global ARMET-like Protein 1 Market by Region

7. North American ARMET-like Protein 1 Market

• 7.1 Overview
• 7.2 North American ARMET-like Protein 1 Market by Type
• 7.3 North American ARMET-like Protein 1 Market by Application
• 7.4 United States ARMET-like Protein 1 Market
• 7.5 Mexican ARMET-like Protein 1 Market
• 7.6 Canadian ARMET-like Protein 1 Market

8. European ARMET-like Protein 1 Market

• 8.1 Overview
• 8.2 European ARMET-like Protein 1 Market by Type
• 8.3 European ARMET-like Protein 1 Market by Application
• 8.4 German ARMET-like Protein 1 Market
• 8.5 French ARMET-like Protein 1 Market
• 8.6 Spanish ARMET-like Protein 1 Market
• 8.7 Italian ARMET-like Protein 1 Market
• 8.8 United Kingdom ARMET-like Protein 1 Market

9. APAC ARMET-like Protein 1 Market

• 9.1 Overview
• 9.2 APAC ARMET-like Protein 1 Market by Type
• 9.3 APAC ARMET-like Protein 1 Market by Application
• 9.4 Japanese ARMET-like Protein 1 Market
• 9.5 Indian ARMET-like Protein 1 Market
• 9.6 Chinese ARMET-like Protein 1 Market
• 9.7 South Korean ARMET-like Protein 1 Market
• 9.8 Indonesian ARMET-like Protein 1 Market

10. ROW ARMET-like Protein 1 Market

• 10.1 Overview
• 10.2 ROW ARMET-like Protein 1 Market by Type
• 10.3 ROW ARMET-like Protein 1 Market by Application
• 10.4 Middle Eastern ARMET-like Protein 1 Market
• 10.5 South American ARMET-like Protein 1 Market
• 10.6 African ARMET-like Protein 1 Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global ARMET-like Protein 1 Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Thermo Fisher Scientific
  • Company Overview
  • ARMET-like Protein 1 Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Bio-Techne
  • Company Overview
  • ARMET-like Protein 1 Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Scientists Helping Scientists
  • Company Overview
  • ARMET-like Protein 1 Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Abcam Limited
  • Company Overview
  • ARMET-like Protein 1 Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 FUJIFILM Irvine Scientific
  • Company Overview
  • ARMET-like Protein 1 Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 BD Biosciences
  • Company Overview
  • ARMET-like Protein 1 Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Bio-Rad Laboratories
  • Company Overview
  • ARMET-like Protein 1 Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 BPS Bioscience
  • Company Overview
  • ARMET-like Protein 1 Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Elabscience
  • Company Overview
  • ARMET-like Protein 1 Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Yisheng Biotechnology
  • Company Overview
  • ARMET-like Protein 1 Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us